The Role of Heat Shock Proteins in Leukemia

Úloha bielkovín tepelného šoku v leukémii

Klikova K., Pilchova I., Stefaniška A., Hlatok J., Dobrota D., Racay P.

Department of Medical Biochemistry, Jessenius Faculty of Medicine, Comenius University, Martin, Slovak Republic

Summary
Heat shock proteins (HSPs) HSP27, HSP70 and HSP90 are molecular chaperones; their expression is increased after exposure of cells to conditions of environmental stress, including heat shock, heavy metals, oxidative stress, or pathologic conditions, such as ischemia, infection, and inflammation. Their protective function is to help the cell cope with lethal conditions. The HSPs are a class of proteins which, in normal cells, are responsible for maintaining homeostasis, interacting with diverse protein substrates to assist in their folding, and preventing the appearance of folding intermediates that lead to misfolded or damaged molecules. They have been shown to interact with different key apoptotic proteins and play a crucial role in regulating apoptosis. Several HSPs have been demonstrated to directly interact with various components of tightly regulated caspase-dependent programmed cell death. These proteins also affect caspase-independent apoptosis by interacting with apoptotic factors. Heat shock proteins are aberrantly expressed in hematological malignancies. Because of their prognostic implications and functional role in leukaemias, HSPs represent an interesting target for antileukemic therapy. This review will describe different molecules interacting with anti-apoptotic proteins HSP70 and HSP90, which can be used in cancer therapy based on their inhibition.

Key words
heat shock proteins – inhibitors – leukemia – apoptosis

Súhrn
Bielkoviny tepelného šoku (heat shock proteins – HSPs) HSP27, HSP70 a HSP90 sú molekulárne súperény, ktorých expresia sa zvyšuje po ovplyvnení buniek pôsobením otvarých stresových podmienok, ako napríklad tepelný šok, toxický alebo pre patických podmienkach ako napr. ischemia, infekcia a zápal. Ich protectivná úloha pôsobí buňku vytvoriť sa s ležnými podmienkami. HSPs sú skupina bielkovín, ktoré v zdravých bunách zapôsobujú na zdravie a samoreguláciu funkcií, ktoré vedú ku tvorbe chýbne založených alebo poškodených molekul. Ukázalo sa, že interagerajú s rôznymi klúčovými bielkovinami a zohrávajú úlohu v regulácii apoptózy. Viacero bielkovín tepelného šoku preukázali príjaznú interakciu s rozličnými zložkami úzko regulovaného kapazitno-zváženeho programovanej bunkovej smrti. Tieto bielkoviny rovnako ovplyvňujú kapazitno-nezvážene druhu apoptózu vzbou s apoptotickými faktormi. Bielkoviny tepelného šoku sú odlišne exprimované v hematológických malignitách. Z dôvodu ich asociácie s úlohou v leukémias, HSPs prezentujú zaujímave ciele v antileukemickej terapii. Tento prehliadkový článok opisuje rôzne molekuly interagujúce s antitumorálnymi bielkovinami HSP70 a HSP90, ktoré by mali byť využité v nábojovej terapii na základe ich inhibície.

Kľúčové slová
bielkoviny tepelného šoku – inhibitor – leukémia – apoptóza
THE ROLE OF HEAT SHOCK PROTEINS IN LEUKEMIA

Introduction
The group of proteins involved in folding and unfolding of other proteins were originally called stress proteins or heat shock proteins (HSPs). They are found in all living organisms, from bacteria to humans [1]. HSPs were first discovered in 1962 by Ritossa as a set of highly conserved proteins whose expression was induced in salivary gland chromosome puffs of Drosophila melanogaster in response to transient exposure to elevated temperatures. The cellular response to stress is induced at the molecular level by induced synthesis of heat shock proteins [2]. HSPs have been classified into six families according to their molecular sizes: the small HSPs (between 15–30 kDa), HSP40, HSP60, HSP70, HSP90 and HSP100 [3]. Within each family, there are members that are constitutively or inducibly regulated and/or targeted to different compartments. The functions of HSP90 are in the cytosolic and nuclear compartments, whereas the function of GRP94 is an analogue of endoplasmic reticulum. The members of the HSP70 family are located in cytosol; for example, the major inducible HSP70 (called HSP70 or HSP72) or the constitutively expressed HSC70, mHSP70 is a mitochondrial protein, whereas GRP78 is localized in the endoplasmic reticulum [4]. HSPs with high molecular weight (e.g., HSP70 and HSP90) are ATP dependent chaperones that require co-chaperones to modulate their conformation and binding to ATP. The function of HSP70, ATP dependent molecular chaperone, is to assist in folding of newly synthesized polypeptides, the assembly of multi-protein complexes and the transport of proteins across cellular membranes. The HSP70 co-chaperones are proteins like HSP40, CHIP, HOP, HIP, BAG-1 and BAG-3. Co-chaperones of HSP90 include proteins such as Cdc37, p23, Ah1, PPS, HOP and CHIP. The small HSPs are ATP independent chaperones [5,6]. The pleiotropic activities of HSPs can contribute to tumorigenesis because they play an essential role as molecular chaperones that provide the cancer cells with an opportunity to alter protein activities, components of cell cycle, kinases and other proteins that influence cell growth [7]. The abnormally high activities and/or expressions of HSP27, HSP70 or HSP90 are increased after different kinds of stimuli including oxidative stress, hyperthermia, radiation, ligation to death receptors or addition of anticancer drugs [8]. The small family of transcription factors called heat shock factors (HSFs) are the regulators of stress-inducible expression of HSP genes. They bind consensus heat shock elements (HSEs) which are located at various distances upstream of the site of transcription initiation [9]. It is known that the stress-induced formation of homo-trimer of HSF1 and a number of post-translation modifications convert the factor into an active form that moves toward a nucleus and binds within the S’ promoter regions of HSP genes that is critical point to trigger of HSP transcription. In humans, three heat shock factors HSF1, HSF2 and HSF4 have been characterized. The ubiquitously expressed HSF1 has a pivotal role in the stress-induced expression of HSP genes. Activation of HSF2 happens during inhibition of the ubiquitin-dependent proteasome, hemin-induced cell differentiation or in specific stages of development [10,11]. HSF4 constitutively binds to DNA and appears to be preferentially expressed in human tissues, such as heart, pancreas, skeletal muscle, brain and lung. It has been suggested to be an inhibitor of stress-induced gene expression [12,13]. HSF4 consists of two isoforms HSF4a and HSF4b, which are derived by alternative RNA splicing events. HSF4b has the transcriptional potential, whereas HSF4a does not [13–16]. HSF4 may have physiological roles during development [17]. It has been shown recently that mutations of HSF4 are associated with dominant inherited cataracts in humans [18]. The group of dr. Fujimoto has found that HSF4 has a major HSE-binding activity specifically in the lens extract. They generated mice in which the HSF4 gene was mutated. The anomalies of the lens revealed novel HSF4 target genes that are essential for cell growth and differentiation [19]. The over-expression of HSFs has been associated with therapeutic resistance and with a poor clinical outcome in acute leukemias and myelodysplastic syndrome [20,21]. In this way, HSPs may have important therapeutic implications and they can be targeted by specific drugs and/or inhibitors.

HSPs in apoptosis
One of the mechanisms to maintain cancer cell survival are the cytoprotective functions of stress-inducible HSP proteins, such as HSP27, HSP70 and HSP90. The metabolic and signal transduction pathways are extensively re-wired in the cancer cells, thereby becoming dependent on these proteins. Their anti-apoptotic effect is associated with key effectors of apoptosis (Fig. 1) [8]. HSP70 has an important role at the death receptors level because it binds to DR4/5 (death receptors 4 and 5), thereby inhibiting TRAIL-induced assembly and activity of DISC (death inducing signaling complex) [22]. Antiapoptotic protein HSP70 binds and blocks c-Jun N-terminal Kinase (JNK) activity at the pre-mitochondrial level. The activation of JNK signaling pathway and activation of caspase 3 is induced by deficiency of HSP70 that triggers apoptosis by hyperosmolality [23]. Inhibition of Bax translocation and its insertion by HSP70 is a consequence of prevention to permeabilize the mitochondrial membrane and to release cytochrome c and apoptosis inducing factor (AIF) [24]. It has been demonstrated that HSP70 and HSP90 bind to the apoptotic protease activating factor 1 (Apaf-1) and inhibit its oligomerization and further recruitment of procaspase-9 to the apoptosome [25]. The lysosomal membrane permeabilization is inhibited by HSP70 thereby preventing proteases cathepsines to release [26, 27]. The genes coding for HSPs are induced in hemin-induced differentiation of human K-562 erythroleukemic cells [28]. One of another mechanism of HSPs is the subcellular localization that determines whether a cell is to die or to differentiate. Laneuva and his colleagues have demonstrated that a nuclear HSP70 has the essential role for erythroid differentiation. HSP70 and caspase-3 are accumulated in the nucleus of the erythroblast during formation of red blood cells [29, 30]. The erythropoiesis requi-
res transcription factor GATA-1 which directly binds to HSP70. As a result, erythroblasts continue their differentiation process instead of dying by apoptosis [31].

Antiapoptotic function of HSP90 can be explained by its chaperone role assuring the stability and activity of different cellular proteins, kinases and transcription factors, such as NF-κB, p53, Akt, Raf-1 and JNK. It has been demonstrated that HSP90α gene expression could be repressed by p53 in UV-irradiated cells [32]. HSP90 interacts with and stabilizes receptor RIP (receptor interacting protein). Upon ligation of TNF-α, RIP-1 is recruited to the receptor and promotes the activation of NF-κB and JNK. Degradation of RIP-1 in the absence of HSP90 precludes activation of NF-κB mediated by TNF-α and sensitizes cells to apoptosis [33]. NF-κB signaling pathway is regulated by HSP90 via IKK complex, which is composed of two catalytic p65/p50 subunits and one regulatory subunit – IκB [34]. The anti-apoptotic action of HSP90 is reflected by its capacity to interact with phosphorylated serine/threonine kinase Akt/PKB, a protein that generates a survival signal in response to growth factor stimulation. Interaction HSP90 with phosphorylated Akt leads to phosphorylation of proapoptotic Bcl-2 family protein Bad and caspase-9, leading to their inactivation and to cell survival [35]. Akt has been shown to phosphorylate IκB kinase, which results in promotion of NF-κB mediated inhibition of apoptosis [36].

**HSP90 structure**

HSP90 is abundantly expressed in the cytoplasm of most human cells and makes up 1–2% of cytosolic proteins [37]. Five isoforms of HSP90 have been identified so far: HSP90AA1 (HSP90α1), HSP90AA2 (HSP90α2), HSP90AB1 (HSP90β), HSP90B1...
(GRP94), TRAP1 (mitochondrial HSP90), HSP90ON is an artefact [38]. Prominent cytoplasmic isoforms are HSP90α (inducible form) and HSP90β (constitutive form) that are expressed by two distinct genes [39]. All of the mammalian HSP90 isoforms share a similar structure. HSP90 exists as a homodimer, which contains three relevant domains: A, the C-terminal dimerization domain contains EEVD motif that enables the binding to tetrapeptide repeat-binding (TRP) domain of co-chaperones, B: the charged middle linker region with high affinity for co-chaperones and the client proteins, and C: the adenine binding N-terminal domain [40,41], which is absent in HSP90ON [42]. The N-terminal dimerization of HSP90 stimulates the intrinsic and essential ATPase activity which is controlled by set of accessory proteins called co-chaperones [43].

**HSP90 client proteins**

The chaperone function of HSP90 ensures the correct conformation, intracellular localization, activity and proteolytic turnover of a various proteins that are implicated in cell growth, differentiation and survival [44]. HSP90 client proteins play a role upon binding and hydrolysis of ATP and in the conformational changes of HSP90. The essential role of HSP90 is important for stability and function of many oncogenic client proteins that include apoptotic mediators (Bcl-2, Apaf-1), cell cycle regulatory proteins (hTERT, CDK4), tumor suppressor genes (p53) [45], transcription factors (HSF-1, HIF-1), signaling molecules (Src, Lck, Akt, Raf-1), steroid hormone receptors, such as estrogen, androgen, progesterone, glucocorticoid receptors and mutant fusion kinase (BRC-ARI1) [44]. Inhibition of HSP90 ATPase activity disrupts the "folding cycle", which involves multiple co-chaperone proteins leading to the destabilization, ubiquitination and degradation of client proteins, such as signaling proteins (the ligand-dependent transcription factors) or signal transducing kinases by the proteasome [39].

**HSP70 structure**

The stress inducible form of heat shock protein HSP70 is upregulated by HSF. HSP70 protects cells from apoptosis, both upstream and downstream of the effector caspase activation [46]. HSP70 inhibits the apoptotic pathway by binding to Bax and Apaf-1 preventing them from continuing the apoptotic cascade [29]. A novel HSP70 co-chaperone called HSP70 binding protein 1 (HspBP1), an intracellular protein abundant in tissue [47], was found to bind to the ATPase domain of HSP70 and inhibit its ability to refold denatured proteins [48]. The molar ratio of HspBP1 to HSP70 in cells might be expected to be an important determinant of the interaction between these two proteins as well as of the function of the resulting complex [49]. The role of HSP70 as ATP dependent molecular chaperone is to assist in folding of newly synthesized polypeptides, to assemble the multi-protein complexes and to transport the proteins across cellular membranes [50]. HSP70 contains two distinct functional domains: a peptide binding domain (PBD) includes a carboxy-terminal chaperone EEVD motif which is responsible for substrate binding and refolding, and the amino-terminal ATPase domain (ABD) [37].

**HSP70 client proteins**

The ABD domain releases the client proteins of HSP70 after ATP hydrolysis. The co-chaperones bind to HSP70 and regulate its chaperone function. There are three classes of groups of HSP70 co-chaperones: 1. the co-chaperones with J-domain are large groups that bind to the HSP70 ABD and stimulate the low ATPase activity of this chaperone, such as HSP40, 2. the nucleotide exchange factor co-chaperones catalyze the release of ADP which is necessary for completion of HSP ATPase cycle, such as BAG-1, HSP110 and HSPB1. 3. the TPR domain co-chaperones that bind to the C-terminal EEVD motif, such as Hop and CHIP. Both of them are essential co-chaperones of HSP70 and HSP90 complexes and CHIP has an ubiquitin ligase activity that is implicated in the ubiquitination of HSP7 client proteins [37]. BAG-1 is the apoptosis regulatory protein interacting with HSP70 that simultaneously regulates the activities of proteins, such as Bcl-2 and Raf-1. HSP70/BAG-1 complex regulates the cell growth in the response of the stress and activity of Raf-1/Erk kinase [51,52].

**Overexpression of HSP90 and HSP70 in hematological malignancies**

The basal level of HSP protein expression is low or absent in normal, non-transformed cells and tissues. In contrast, the HSPs are abundantly expressed in hematological malignancies, including lymphoid diseases and chronic (CML) or acute myeloid leukemias (AML). Cancer cells need high levels of HSPs for their survival [53]. Over 90% of cases of CML possess a human fusion oncogene Bcr-Abl as a result of reciprocal translocation between chromosome 9 and 22 [54]. Bcr-Abl positive cells are characterized by increased proliferation with high resistance to anti-leukemia drugs [55]. HSP70 and HSP90 bind and stabilize BCR-ABL tyrosine kinase and were found to be overexpressed in CML blast crisis and in cell line K562 established from CML primary cells [56]. The cell proliferation could be stimulated by upregulation of HSP70 and HSP90 through the control of BCR-ABL tyrosine kinase functions, which phosphorylates and activates Akt that, in turn, inactivates Bad and caspase-9 and phosphorylates STAT5. Phosphorylated STAT5 binds DNA and increases the expression of anti-apoptotic protein Bcl-xL. In contrast, when the activity of tyrosine kinase BCR-ABL and PI3-K is inhibited with imatinib or wortmannin, decreased expression of HSP70 and downregulation of STAT5 activity were observed [22]. The conformational stability and activation of mutant oncoproteins, such as c-KIT, FLT3-ITD or BCR-ABL, are strongly dependent on HSPs, leading to poor prognosis in AML [57]. The inhibition of HSP90 using 17-AAG reduces the level of the FLT-3-ITD, downstream STAT5 activity [58]. In peripheral blood and bone marrow of patients diagnosed with de novo acute myeloblastic leukemia as well as in leukemia cell lines (K-562, Jurkat and CCRF-CEM), increased expression of HSP90α at the level of mRNA was observed [49]. Simi-
lar results were published in the study by Thian et al. where they investigated the expression of HSP90a in different leukemia cell lines (HL-60, NB4, Molt-4) and human bone marrow mononuclear cells derived from acute leukemia patients. In the untreated patients and in patients in remission, higher expression of HSP90a compared to cells from healthy individuals was observed [59]. In our study, we found significantly higher protein levels of HSP27 (p < 0.001), HSP70 (p < 0.001), HSP90α (p < 0.001), HSP90β (p < 0.001) and GRP75 (p < 0.05) in K-562 cells compared to HL-60 cells while difference in GRP78 protein level between analyzed cell lines was not significant. The highest differences were observed in the levels of HSP27 (30.9 fold higher expression in K-562 cells) and HSP70 (14.5 fold higher expression in K-562) [60].

HSPs inhibitors – pharmacological targets

As molecular chaperons, HSP90 and HSP70 have been implicated in pathogenesis of multiple diseases, such as leukemia [61–64], neurodegenerative disorders [65], cancer [66], and infectious disease [67]. HSPs are interesting targets in therapy of hematological malignancies because of their antiapoptotic and tumourigenic properties [68]. Several oncogenic kinases, such as receptor tyrosine kinase FLT3 involved in AMLs, fusion proteins NPM-ALK and BCR-ABL involved in chronic myeloid leukemia and anaplastic large-cell lymphomas are client proteins for HSP90 [69,70]. Studies in Bcr-Abi human leukemia cells suggest that HSP70 is a promising therapeutic target for reversing drug resistance, probably due to its ability to inhibit caspase-dependent and caspase-independent death pathways both upstream and downstream of the mitochondrial signaling [22,71]. One of the strategies to modulate intracellular regulatory pathways is to develop several direct inhibitors of HSP70 and HSP90 that would be useful alone but also in combination with other drugs in leukemia treatment.

The inhibitors of HSP70

One of the contributing factors of HSP70 is its strong connection to apoptosis; relatively little progress has been made in bringing HSP70 inhibitors to the clinic [72]. The complexity of HSP70 functions (e.g. folding, degradation, trafficking and remodeling) and its ubiquitous expression patterns create numerous challenges in designing safe and effective therapeutics [73]. Specific HSP70 inhibitors are now investigated in preclinical models but only one of these agents, AG-858, has already reached clinical trials (Tab. 1) [74].

HSP70 inhibitors fall into three basic classes:
1. Small molecule inhibitors,
2. Aaptars,
3. Antibodies [75].

The class of the small molecule inhibiting HSP70 is represented by e.g. pifithrin-μ (PFT-μ), identified as a specific inhibitor of inducible HSP70 (Tab. 1). PFT-μ interferes with the carboxyterminal peptide-binding domain (CBD) of HSP70 and disrupts its association with client proteins [76]. The first study demonstrating significant antileukemic in vitro effects of PFT-μ alone and in combination with different antineoplastic drugs had been evaluated in ALL and AML cell lines as well as in primary AML blasts [77].

The second class of inhibitors are DNA aptamers, such as JH6, JH19, and K19 [78] or RNA aptamers, for example Antisoma [79] that are isolated from a large pool of nucleic acids by selection process called SELEX. Aptamers have the ability to bind to proteins and specifically inhibit their functions with minimal or no harmful side-effects [80]. Only few HSP70-targeting aptamers were developed, one example is the most potent aptamer A17 that binds to the CBD of HSP70 and disrupts the function of HSP70 [81]. The dual testing of aptamers with H570/HSP90 inhibitors could be the next step in leukemia treatment. The
mechanism of action of HSP70 aptamers in leukemia is still unknown.

The third strategy for developing HSP70 inhibitors utilizes the immune system. Exciting new strategies that might affect future anti-leukemia immunotherapy include treatment using monoclonal antibodies [82]. The role of HSP70 antibody on virus production was investigated. Incubation of two rabbit transformed T-cell lines; RH/R30 (asymptomatic) and RH/K34 (leukemogenic) with rabbit anti-HSP70 antibodies prevented the production of human T-cell lymphotropic virus type I (HTLV-I) specifically in the leukemogenic cell line. The results indicated a relationship between HSP70 and virus production [83]. Recently developed monoclonal antibody, cmiHSP70.1, was used in treatment of colon cancer mouse model (CT26) that led to a significantly decreased tumor weight and volume [84]. It is the only HSP70-targeted therapy currently in clinical trials (clinicaltrials.gov).

An adenosine-derived compound binding to amino-terminal ATPase domain of HSP70 is called VER-155008. It inhibits the chaperone activity of proteins of the HSP70 family [37]. VER-155008 caused a dose-dependent inhibition of cytochrome-dependent AML cell proliferation both in suspension cultures and in a colony forming assay. HSP70 inhibition has both anti-leukemic and pro-apoptotic effects when tested alone, and the combination of VER-155008 and 17-DMAG (Tab. 1) inhibitors of HSP90 seems to have additive anti-leukemic effects for primary human AML cells in vitro [67]. Methylene blue (MB) is a phenothiazine with radio and photosensitizing properties and anti-tumor activity. The group of dr. Kirszberg has shown that MB (Tab. 1) was capable of inhibiting the in vitro growth of erythroleukemic cells with multidrug resistance (MDR). Lymphocytes and erythroleukemic cells were much more sensitive to the effects of MB than melanoma cells and melanocytes [87]. In our study, we have documented that the effect of methylene blue was different on the relative viability of both leukemia cell lines K-562 and HL-60. MB at concent-

ration 1 μmol/l and higher, decreased cell viability of HL-60 already after 24 hours. Impact of methylene blue on the viability of K-562 was slow and potent decrease of relative viability was observed after 72 hours of incubation (not published).

Inhibitors of HSP90

Inhibition of HSP90 function has been shown to cause degradation of client proteins via the ubiquitin-proteasome pathway [88], which results in depletion of multiple oncoproteins, in down-regulation of signals propagated through oncogenic signaling pathways and modulation of the malignant phenotype [89].

Inhibitors of HSP90 are classified into four groups:

1. benzoquinone ansamycins and their derivatives,
2. radicicol and its derivatives,
3. small synthetic inhibitors,
4. other inhibitors [90].

Geldanamycin (GM) is a benzoi

awnone ansamycin, which inhibits the ATPase activity of HSP90 by competing with ATP for binding to the N-terminal nucleotide binding site, leading to ubiquitin mediated proteosomal degradation of HSP90 client proteins [91]. GM was never evaluated in clinical trials because of its poor solubility, limited in vivo stability and significant hepatotoxicity in animals [92,93]. Geldanamycines analogues have been developed that maintain similar anticancer activities but with an improved toxicity profile. 17-AAG (17-allylamino-17-desmethoxygeldanamycine) entered Phase I trials in 1999 and first therapeutic activity has been seen in melanoma, breast cancer, prostate cancer and multiple myeloma [94]. It is now in clinical trials [95], which mainly focus on specific HSP90 chaperoning targets, such as leukemia expressing Bcr-Abl and Her-2 positive breast cancer [96,97]. 17-AAG has low water-solubility, instability in solution and a lack of oral bioavailability (Tab. 2) [37]. The N,N-di-methylthelylamino analogue of 17-AAG (17-DMAG), more water-soluble, has entered Phase I clinical trials in various types of leukemia (Tab. 2) and displayed higher oral bioavailability, tolerable toxicity, increased stability compared with 17-AAG [98]. 17-DMAG with arsenic trioxide has emerged as a promising therapeutic combination since they synergize to induce apoptosis and mitotic arrest in leukemic cells [99].

Another hydroquinone hydrochloride analogue of 17-AAG is IPI-504 (Rutamycin) that has improved water solubility properties (Tab. 2) [100]. IPI-504 has entered the Phase II clinical trials to evaluate its potential for treating Ph-chromosome positive CML that has become resistant to therapy with tyrosine kinase inhibitors [101].

Geldanamycin-derived product, such as 17-AAG, is being clinically tested in combination with chemotherapy inimitin (STI-571). This agent is an effective therapy for CML characterized by the expression of the oncoprotein BCR-ABL [102]. Since BCR-ABL is a client HSP90 protein, a combination with 17-AAG is being tested in phase I clinical trials in BCR-ABL positive leukemias with encouraging results [103].

A new approach to targeting HSP90 began with the observation that the antibiotic novobiocin binds with low affinity to a C-terminal region of HSP90 resulting in disruption of HSP90 chaperone activity with subsequent depletion of several client proteins, including Her-2, Raf-1 and mutant p53 [104,105]. More potent analogs of novobiocin have been developed, designated KU155, binds directly to HSP90 and suppresses cell proliferation of Jurkat T-lymphocytes. KU155 was found to be a potent inducer of mitochondria-mediated apoptosis and caused G2/M arrest of leukemic cells. Indeed, KU153 was found to exert more potent antiproliferative effects than 17-AAG [106].

The second group of HSP90 inhibitors are radicicol and its derivatives. Radicicol, a natural macrocyclic antifungal antibiotic isolated from the fungus Monocillium nordimini, binds to the N-terminal ATP pocket of HSP90 leading to destabilization of HSP90-client proteins, such as Raf-1 [107]. Radicicol displays strong anti-tumor properties in vitro but not in vivo probably because of its chemical instability in tumor xenografts models [108]. This scaffold has led to gene-
### Tab. 2. HSP90 inhibitors used in hematological malignancies.

<table>
<thead>
<tr>
<th>HSP90 inhibitors</th>
<th>Clinical status</th>
<th>Combination</th>
<th>Disease</th>
<th>NCF/references</th>
</tr>
</thead>
<tbody>
<tr>
<td>alvespimycin (17-DMAG)</td>
<td>phase I</td>
<td>no</td>
<td>relapsed chronic lymphocytic leukemia, small lymphocytic lymphoma and B-cell prolymphocytic leukemia</td>
<td>NCT01126502</td>
</tr>
<tr>
<td>tanespimycin (17-AAG)</td>
<td>phase I</td>
<td>w/u rituximab</td>
<td>B-cell chronic lymphocytic leukemia, prolymphocytic leukemia, refractory chronic lymphocytic leukemia</td>
<td>NCT00098488</td>
</tr>
<tr>
<td></td>
<td></td>
<td>w/o cytarabine</td>
<td>relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, chronic myelomonocytic leukemia, or myelodysplastic syndromes</td>
<td>NCT00098423 [115]</td>
</tr>
<tr>
<td>retaspimycin (IPI-504)</td>
<td>phase III</td>
<td>no</td>
<td>relapsed or relapsed and refractory multiple myeloma leukemic progenitor and stem cells in chronic myeloid leukemia mice</td>
<td>[116] [101]</td>
</tr>
<tr>
<td>ganetespib (STA-9090)</td>
<td>phase I</td>
<td>no</td>
<td>acute myeloid leukemia acute lymphoblastic leukemia blast-phase chronic myeloid leukemia</td>
<td>NCT00964873</td>
</tr>
<tr>
<td></td>
<td>phase I-II</td>
<td>w/o Plerixafor, AC220</td>
<td>acute myeloid leukemia high risk myelodysplastic syndrome</td>
<td>NCT01236144 [117]</td>
</tr>
<tr>
<td>CNF2024/BIIB021</td>
<td>phase I</td>
<td>no</td>
<td>B-cell chronic lymphocytic leukemia</td>
<td>NCT00344786 [112]</td>
</tr>
<tr>
<td></td>
<td>phase II-III</td>
<td>no</td>
<td>chronic myeloid leukemia myelodysplastic syndromes, chronic myelomonocytic leukemia, acute myeloid leukemia</td>
<td>NCT00449761</td>
</tr>
<tr>
<td></td>
<td>phase I</td>
<td>with imatinib mesylate</td>
<td>chronic myeloid leukemia and acute myeloid leukemia cell lines</td>
<td>NCT00668218 [118]</td>
</tr>
<tr>
<td></td>
<td>in vitro</td>
<td>with tanespimycin</td>
<td>chronic myeloid leukemia and acute myeloid leukemia cell lines</td>
<td>NCT00668218 [118]</td>
</tr>
<tr>
<td>panobinostat (LBHS89)</td>
<td>phase I</td>
<td>with imatinib mesylate</td>
<td>chronic myeloid leukemia and acute myeloid leukemia cell lines</td>
<td>NCT00668218 [118]</td>
</tr>
<tr>
<td></td>
<td>phase II</td>
<td>no</td>
<td>chronic myeloid leukemia and acute myeloid leukemia cell lines</td>
<td>NCT00668218 [118]</td>
</tr>
<tr>
<td></td>
<td>phase I-I</td>
<td>bortezomib</td>
<td>multiple myeloma</td>
<td>NCT00457782 [109]</td>
</tr>
<tr>
<td></td>
<td>phase I-I</td>
<td>with decitabine, isoretinoin, cytarabine, etoposide, idarubicine, alvocidib, doxorubicin, imatinib mesylate, methotrexate, pegaspargase, prednisone, vincristine, sorafenib, bortezomib</td>
<td>advanced solid tumors, relapsed or refractory non-Hodgkin's lymphoma, acute myeloid leukemia, acute lymphocytic leukemia or chronic myeloid leukemia in blast crisis, myelodysplastic syndrome</td>
<td>NCT00163907 [109]</td>
</tr>
<tr>
<td>KW-2478</td>
<td>phase I-I</td>
<td>no</td>
<td>multiple myeloma</td>
<td>NCT00275080 [109]</td>
</tr>
<tr>
<td>vorinostat (SAHA)</td>
<td>phase I-I</td>
<td>no</td>
<td>multiple myeloma</td>
<td>NCT00163907 [109]</td>
</tr>
<tr>
<td></td>
<td>phase I-I</td>
<td>with decitabine, isoretinoin, cytarabine, etoposide, idarubicine, alvocidib, doxorubicin, imatinib mesylate, methotrexate, pegaspargase, prednisone, vincristine, sorafenib, bortezomib</td>
<td>advanced solid tumors, relapsed or refractory non-Hodgkin's lymphoma, acute myeloid leukemia, acute lymphocytic leukemia or chronic myeloid leukemia in blast crisis, myelodysplastic syndrome</td>
<td>NCT00275080 [109]</td>
</tr>
</tbody>
</table>

Rate radical derivates with improved solubility and stability. Several oxime derivatives and cycloproparadicol have been developed, such as KFS8333 that induced apoptosis in chronic myeloid cell line K-562 [109].

The class of synthetic inhibitors of HSP90 is composed of inhibitors based on purine scaffold. The first synthetic class of
such scaffold was the PU series, such as PU-H71 and PU-D28. They were developed based on the binding of ADP and geldanamycin inside HSP90 ATP-binding site in combination with crystallographic and docking-based data. These PU mimic the condensation of ADP in the pocket and have a higher affinity for HSP90 than ADP [110]. CNF 2024/BIBB021 is a purine scaffold orally bioavailable that induces Hodgkin’s lymphoma cell death through inhibition of NF-κB signaling pathway [111]. This agent has been evaluated in phase I clinical trial in patients with B-cell CML (Tab. 2) [112].

The other types of inhibitors of HSP90 are the molecules that block the interaction between HSP90 and its client protein or co-chaperone. Shephardin, a peptidomimetic, is an antagonist of the interaction between HSP90 and its anti-apoptotic client protein survivin that is a key regulator of tumor cell viability [113]. It can interact with the ATP pocket of HSP90 as well as to affect a range of HSP90 client proteins suggesting it has a different mode of action. Shephardin has anti-leukemia activity in animal models [114]. Most details of the client/chaperone interactions are currently unknown; therefore, the strategy of targeting these associations is a challenge for further investigation.

Conclusions

The possibility to compare effects of inhibitors of the HSPs in leukemic cells offers the unique opportunity to analyze the biochemistry of these malignancies and their role in apoptosis of this disease. Given the overall poor prognosis of leukemia, great interest surrounds the development of novel and less toxic targeted therapies against signaling pathways that are aberrantly activated in leukemic patients and sustain leukemic cell survival and proliferation.

References

22. Lee JS, Lee J, Seo JS. HSP70 deficiency in activity of c-Jun N-terminal kinase, extracellular signal regulated kinase, and caspase-3 in hypoxia-induc- 


